3,187 reports of this reaction
2.6% of all OCRELIZUMAB reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for OCRELIZUMAB, manufactured by Genentech, Inc.. There are 3,187 FDA adverse event reports linking OCRELIZUMAB to HEADACHE. This represents approximately 2.6% of all 123,105 adverse event reports for this drug.
OCRELIZUMAB has an overall safety score of 78 out of 100. Patients taking OCRELIZUMAB who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for OCRELIZUMAB, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for OCRELIZUMAB:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 3,187 FDA reports for OCRELIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.6% of all adverse event reports for OCRELIZUMAB, making it a notable side effect.
If you experience headache while taking OCRELIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.